Digoxin-BSA is an antigen–adjuvant conjugate composed of Digoxin covalently linked to bovine serum albumin (BSA), designed to enhance the production of antigen-specific antibodies in vaccine and immunological models, while preserving native protein folding and major epitopes, improving cross-presentation efficiency, and promoting robust antigen-specific T-cell responses for immunogenicity and antibody development research.